An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A [amibegron] 350 mg Twice a Day in Elderly Patients With Generalized Anxiety Disorder With an Optional Twenty-Four Week Extension.

Trial Profile

An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A [amibegron] 350 mg Twice a Day in Elderly Patients With Generalized Anxiety Disorder With an Optional Twenty-Four Week Extension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Amibegron (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Nov 2008 Actual patient number (55) added as reported by ClinicalTrials.gov
    • 02 Nov 2008 Additional trial identifier 'EudraCT2006-004147-33' added as reported by ClinicalTrials.gov.
    • 02 Nov 2008 Planned end date (Aug 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top